SiteMap CMC home migration 101 the consortium  

Protein Discovery

Structure

Signaling

Transgenic and Knockout Mouse

Modeling

Biomaterials

Imaging and Photomanipulation

Communications

Bioinformatics

 

 

Contact us
Last updated: January 11, 2005

Copyright 2004, by the Rector and Visitors of the University of Virginia

 

| Phosphoproteomics |

Phosphorylation of Focal Adhesion Kinase (FAK)

Last Updated May 2005

Phosphoproteomics

C18 (-) inhibitorsAlignment / Methods
IMAC (-) inhibitorsAlignment / Methods
C18 (+) inhibitorsAlignment / Methods
IMAC (+) inhibitorsAlignment / Methods
C18 (+) inhibitors (dup)Alignment / Methods
IMAC (+) inhibitors (dup)Alignment / Methods
C18 (+) inhibitors LysCAlignment / Methods
C18 (+) inhibitors LysC + AspNAlignment / Methods
IMAC (+) inhibitors LysC + AspNAlignment / Methods

All Phosphorylation results

Site Position Peptide Abundancea
(+) Inhib(-) Inhib
13T 7 - 19 
 DPNLNHTPSSSAK
 *  
29S 20 - 38 
 THLGTGMERSPGAMERVLK
 * ++++
155Y 153 - 170 
 NDYMLEIADQVDQEIALK
 ++  
386S / 388T 382 - 404 
 QGVRSHTVSVSETDDYAEIIDEE
 *  
386S / 388T 383 - 404 
 GVRSHTVSVSETDDYAEIIDEE
 *  
386S / 390S 381 - 393 
 KQGVRSHTVSVSE
 *  
388T / 390S 381 - 393 
 KQGVRSHTVSVSE
 *  
388T / 392S 382 - 404 
 QGVRSHTVSVSETDDYAEIIDEE
 *  
388T / 397Y 382 - 404 
 QGVRSHTVSVSETDDYAEIIDEE
 *  
390S 382 - 395 
 QGVRSHTVSVSETD
 *  
390S 382 - 404 
 QGVRSHTVSVSETDDYAEIIDEE
 * *
390S 383 - 394 
 GVRSHTVSVSET
 *  
390S / 394T-397Y 382 - 404 
 QGVRSHTVSVSE[TDDY]AEIIDEE
   *
394T-397Y 382 - 404 
 QGVRSHTVSVSE[TDDY]AEIIDEE
   *
397Y 382 - 404 
 QGVRSHTVSVSETDDYAEIIDEE
   ++
406T / 407Y 405 - 416 
 DTYTMPSTRDYE
 *  
570Y 564 - 572 
 DFGLSRYME
 * #
700T / 708S 690 - 709 
 RMRMESRRQVTVSWDSGGSD
 ++++  
722S / 725S-726S 709 - 729 
 DEAPPKPSRPGYPSPR[SS]EGF
 *  
732S 728 - 780 
 GFYPSPQHMVQPNHYQVSGYSGSHG
IPAMAGSIYPGQASLLDQTDSWNHRPQE
 *  
766S 750 - 768 
 SHGIPAMAGSIYPGQASLL
 *  
793T 790 - 808 
 DSGTLDVRGMGQVLPTHLM
 *  
845S 831 - 847 
 RFLVMKPDVRLSRGSIE
 *  
888S 877 - 896 
 KPPRPGAPHLGSLASLNSPV
 ++++  
888S 877 - 904 
 KPPRPGAPHLGSLASLNSPVDSYNEGVK
 *  
888S / 891S 877 - 893 
 KPPRPGAPHLGSLASLN
 *  
888S / 891S 877 - 896 
 KPPRPGAPHLGSLASLNSPV
 *  
888S / 891S / 894S 877 - 896 
 KPPRPGAPHLGSLASLNSPV
 *  
888S / 894S 877 - 896 
 KPPRPGAPHLGSLASLNSPV
 +++  
888S / 894S 877 - 904 
 KPPRPGAPHLGSLASLNSPVDSYNEGVK
 +++  
894S 877 - 896 
 KPPRPGAPHLGSLASLNSPV
 *  
894S 877 - 901 
 KPPRPGAPHLGSLASLNSPVDSYNE
 *  
894S 877 - 904 
 KPPRPGAPHLGSLASLNSPVDSYNEGVK
 ++++  
894S / 898S 877 - 904 
 KPPRPGAPHLGSLASLNSPVDSYNEGVK
 ++  
894S / 898S / 899Y 877 - 904 
 KPPRPGAPHLGSLASLNSPVDSYNEGVK
 *  
894S / 899Y 891 - 904 
 SLNSPVDSYNEGVK
 *  
911S 905 - 918 
 IKPQEISPPPTANL
 * ++++
911S 905 - 924 
 IKPQEISPPPTANLDRSNDK
 ++++  

*Peptides detected only by enrichment with immobilized metal-affinity chromatography (IMAC).

a - Relative phosphopeptide abundance expressed in terms of ion counts (peak heights) observed for the most abundant charge state. Ion counts for the most abundant phosphopeptides are displayed as ++++. Those that exhibit ion currents decreased by a factor of 10,100, and 1000 are shown as +++, ++, and +, respectively. Peptide abundance with (+) inhibitors cannot be compared with abundance without (-) inhibitors.